Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwards Reveals Sapien Launch Plans For Transapical Delivery Method

This article was originally published in The Gray Sheet

Executive Summary

Edwards estimates that the approximately 20%-30% of patients who would otherwise qualify but can’t receive a Sapien valve because their femoral artery is too small would likely make good candidates for the transapical, through the ribcage, route.


Related Content

Edwards Finds Transcatheter Valve Adoption In U.S. Slower Than Expected
Stakeholders Evaluate Impact Of Bundled Payment Initiative On Devices, Patient Care
Societies Gain FDA Go-Ahead, Medicare Coverage To Study New Access Methods For Edward’s Sapien Valve
CMS To Pay Co-Surgeons For Transcatheter Valve Procedures, But At Lower Value Than Sought By Physicians
News In Brief
CMS Policy Sets Boundaries On Transcatheter Valve Procedure
New Products In Brief
The Latest On Transapical: Edwards Talks Up Sapien CAP Data
Edwards Wins Approval For Sapien Just In Time For TCT
Getting Set For Sapien: With Data In, Discussion Moves To Adoption Dynamics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts